摘要
钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)是一类新型口服降糖药,通过抑制钠-葡萄糖共转运蛋白2在近端小管对葡萄糖的重吸收和促进尿糖排泄从而降低血糖水平。近年来研究发现,SGLT2i不仅能降低血糖水平,还能保护心脏和肾脏,显著减少心血管事件,延缓肾功能衰竭的进展,同时,对糖尿病视网膜病变也存在潜在治疗作用。本文就SGLT2i的药理机制及其对心脏、肾脏、视网膜保护机制作一综述,旨在为糖尿病及其并发症的临床防治提供新思路。
Sodium-glucose cotransporter 2 inhibitors(SGLT2i)are a new type of oral hypoglycemic agents that reduce blood glucose level by inhibiting glucose reabsorption by sodium-glucose cotransporter 2 in proximal tubules and promoting urinary glucose excretion.In recent years,studies have found that SGLT2i can not only reduce blood glucose level,but also protect heart and kidney,significantly reduce cardiovascular events and delay progression of renal failure.Meanwhile,SGLT2i also possesses potential therapeutic effect on diabetic retinopathy.The present article makes a review on pharmacological mechanism of SGLT2i and its protective mechanism for heart,kidney and retina,aiming at providing new thinking for clinical prevention and treatment of diabetes mellitus and its complications.
作者
华雅芳
刘晓民
HUA Ya-fang;LIU Xiao-min(Department of Endocrinology,First Affiliated Hospital of Harbin Medical University,Harbin,Heilongjiang,150001,China)
出处
《心血管康复医学杂志》
CAS
2023年第3期312-315,共4页
Chinese Journal of Cardiovascular Rehabilitation Medicine
关键词
心血管疾病
糖尿病并发症
钠-葡萄糖转运体2
Cardiovascular diseases
Diabetes complications
Sodium-glucose transporter 2
作者简介
通讯作者:刘晓民,E-mail:Liuxiaomin157@aliyun.com。
